Avodart (dutasteride) is a prescription medication specifically formulated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. As a potent 5-alpha-reductase inhibitor, it targets the underlying hormonal cause of prostate growth by reducing dihydrotestosterone (DHT) levels. This leads to measurable improvements in urinary flow, reduction in prostate volume, and decreased risk of acute urinary retention and BPH-related surgery. Recommended for long-term management, Avodart offers a mechanism-based approach to controlling progressive symptoms and is typically prescribed when symptoms are moderate to severe.

Features

• Contains 0.5 mg dutasteride per soft gelatin capsule
• Dual inhibitor of both type 1 and type 2 5-alpha-reductase enzymes
• Significantly reduces serum dihydrotestosterone (DHT) by up to 90%
• Once-daily oral dosing regimen
• Available in 30-, 90-, and 100-count bottles
• Soft gelatin capsule for improved bioavailability

Benefits

• Reduces prostate size, alleviating urinary obstruction and improving flow
• Decreases the risk of acute urinary retention and future prostate-related surgery
• Provides sustained symptom relief for benign prostatic hyperplasia over the long term
• Minimizes nocturia, frequency, and urgency, improving quality of life
• Prevents disease progression in appropriately selected patients
• Single daily dose supports adherence and consistent therapeutic effect

Common use

Avodart is indicated for the management of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. It is used to improve urinary symptoms, reduce the risk of acute urinary retention, and decrease the need for BPH-related surgery. It may also be used in combination with an alpha-blocker such as tamsulosin for enhanced symptom control in certain patients. Avodart is not approved for use in women or children.

Dosage and direction

The recommended dose is one 0.5 mg capsule taken orally once daily, with or without food. The capsule should be swallowed whole; it must not be crushed, chewed, or opened due to potential mucosal irritation from the liquid contents. Treatment response may be observed as early as 3–6 months, but maximum benefit often requires at least 6–12 months of continuous therapy. Dosage adjustment is not typically required in elderly patients or those with renal impairment, but caution is advised in hepatic impairment.

Precautions

Avodart is contraindicated in women, particularly those who are or may become pregnant, due to risk of fetal harm. Men treated with dutasteride should not donate blood until at least 6 months after the last dose to prevent transmission to pregnant transfusion recipients. Periodic digital rectal examinations (DRE) and prostate-specific antigen (PSA) testing should be continued to monitor for prostate cancer, as Avodart reduces PSA levels by approximately 50% after 6 months. Patients should be counseled on the potential for sexual side effects before initiating therapy.

Contraindications

Avodart is contraindicated in the following populations: women who are pregnant or may become pregnant; pediatric patients; patients with known hypersensitivity to dutasteride, other 5-alpha-reductase inhibitors, or any component of the formulation; and patients with severe hepatic impairment. It should not be used in patients with a history of liver disease without careful monitoring and specialist consultation.

Possible side effect

Common side effects may include:

• Decreased libido (3–5%)
• Erectile dysfunction (5–8%)
• Ejaculation disorders (1–4%)
• Gynecomastia (1–2%)
• Breast tenderness

Less frequently reported effects include dizziness, rash, and testicular pain. Although rare, allergic reactions such as angioedema involving lip, tongue, or pharyngeal swelling have been reported. Most adverse reactions are reversible upon discontinuation, though some may persist.

Drug interaction

No clinically significant pharmacokinetic interactions have been observed with alpha-blockers (e.g., tamsulosin), ACE inhibitors, calcium channel blockers, or NSAIDs. However, potent CYP3A4 inhibitors such as ritonavir, ketoconazole, or verapamil may increase dutasteride exposure. Concurrent use with other 5-alpha-reductase inhibitors (e.g., finasteride) is not recommended. Caution is advised when co-administering with drugs that are extensively metabolized by CYP3A4.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose is not recommended. Consistent daily dosing is important for maintaining stable DHT suppression.

Overdose

No specific antidote for dutasteride overdose is known. Single doses up to 40 mg have been administered without significant adverse effects. In case of suspected overdose, symptomatic and supportive measures should be instituted. Due to high protein binding, dialysis is unlikely to be beneficial. Medical attention should be sought immediately.

Storage

Store at room temperature (20°–25°C or 68°–77°F), with excursions permitted between 15°–30°C (59°–86°F). Keep the bottle tightly closed and stored in its original container to protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual response to Avodart may vary. Not all uses, precautions, or interactions are listed here. Full prescribing information should be reviewed before use.

Reviews

Clinical trials and post-marketing surveillance demonstrate that Avodart is effective in reducing prostate volume and improving urinary symptoms in the majority of patients. Many urologists report sustained efficacy and good tolerability in long-term management of BPH. Some patients note improved quality of life due to reduced urinary symptoms, though a subset may discontinue due to sexual side effects. Overall, it is considered a valuable option in the pharmacological management of moderate to severe BPH.